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Abstract 
 
Follicular lymphoma (FL) results from the malignant transformation of germinal center 
B cells and is characterized by recurrent genetic alterations providing a direct growth 
advantage or facilitating interaction with tumor microenvironment. In agreement, 
accumulating evidences suggest a dynamic bidirectional crosstalk between FL B 
cells and surrounding non-malignant cells within specialized tumor niches in both 
invaded lymph nodes and bone marrow. Infiltrating stromal cells, macrophages, and 
T/NK cell subsets either contribute to anti-tumor immune response, or conversely 
form a tumor supportive network promoting FL B cell survival, growth, and drug 
resistance. This review depicts the phenotypic heterogeneity and functional plasticity 
of the most important FL cell partners and describes their complex interplay. We also 
unravel how malignant B cells recruit and subvert accessory immune and stromal 
cells to trigger their polarization towards a supportive phenotype. Based on these 
observations, innovative therapeutic approaches have been recently proposed, in 
order to benefit from local anti-tumor immunity and/or to selectively target the 
protective cell niche.  
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1. Introduction  
Follicular lymphoma (FL) is the most frequent indolent lymphoma and is considered 
virtually incurable with high response rates to therapy but frequent relapses [1]. 
Progression to aggressive diffuse large B-cell lymphoma (DLBCL) occurs in about 
35% of cases, an event associated with poor outcome [2]. Malignant FL B cells 
express germinal center (GC) B-cell markers such as BCL6 and CD10, have 
somatically mutated immunoglobulin variable genes with ongoing intraclonal 
diversification, and display a gene expression profile of centrocytes, indicating that 
FL results from the malignant transformation of GC-derived B cells [3]. The genetic 
hallmark of FL is the t(14;18) translocation associated with an overexpression of the 
anti-apoptotic protein BCL2, actively repressed in normal GC B cells. However, this 
founder genetic event is detected at a low frequency in most healthy individuals 
within peripheral blood IgM memory B cells, the so-called FL-like cells (FLLC) [4], 
suggesting that additional driver genetic events are required to complete cell 
transformation. Accordingly, genome-wide profiling has recently shed new lights on 
the mutational landscape in FL and delineated a hierarchical model of successive 
genetic events supporting FL tumorigenesis [1, 5].  
Besides the failure of primary FL cells to survive and grow autonomously in vitro, the 
major role of the microenvironment in FL development and evolution has been 
highlighted by several seminal observations. First, like their normal counterpart, 
malignant FL B cells are found admixed with lymphoid stromal cells, macrophages, 
and follicular helper CD4pos T cells (TFH) in GC-like follicles within invaded lymph 
nodes (LN) [6]. In addition, bone marrow (BM) infiltration found in up to 70% of 
patients at diagnosis is characterized by an ectopic differentiation of lymphoid-like 
stromal cells [7] and local enrichment in CD4pos T cells [8] suggesting a critical 
dependence of malignant B cells to this specific supportive cell niche. Despite these 
similarities, some differences in cell composition and organization exist between LN 
and BM niches [8, 9]. In agreement, different subclones could be detected within BM 
and LN, and BM FL cells are characterized by a lower cytological grade and 
proliferation [9-11]. These data support the hypothesis that trafficking in various 
specific microenvironments could contribute to FL clonal selection and molecular 
heterogeneity [12]. Second, several highly frequent genetic alterations are not 
oncogenic per se but favor the crosstalk of FL cells with neighboring cells. Among 
them, mutations in TNFRSF14/HVEM affecting its expression or binding to the 
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inhibitory receptor BTLA could contribute to the maintenance and supportive activity 
of BTLAhi FL-infiltrating TFH [13, 14]. Moreover, more than 90% of FL cases display 
unusual sites for N-linked glycosylation within their immunoglobulin variable regions 
introduced during the somatic hypermutation process (SHM) [15]. Added glycans 
contain oligomannoses that might interact with C-type lectins expressed by myeloid 
cells in the microenvironment, allowing FL cells to receive antigen-independent but 
cell contact-dependent survival signals through their BCR [16]. Finally, several 
studies based on expression profiling and immunohistochemistry have proposed a 
panel of prognostic biomarkers reflecting the number, activation, and/or spatial 
organization of infiltrating immune cells, further emphasizing the central role of FL 
microenvironment [17]. In the landmark study performed on whole tumor biopsies, 
the clinical outcome of FL patients was primarily predicted by molecular features of 
non-malignant cells and not by specific genetic characteristics of tumor B cells [18]. 
However, these studies led to highly contradictory results, in part due to treatment 
heterogeneity, and remained essentially descriptive without transposition of the data 
into more functional and mechanistic approaches.  
Our current knowledge of the relationship between FL B cells and their 
microenvironment has been hindered by four main technical pitfalls: i) the lack of true 
FL B-cell lines; ii) the lack of relevant transgenic mouse model of FL; iii) the difficulty 
to establish FL xenografts in immunocompromised mice in the absence of T-cell help 
and mature secondary lymphoid organs; iv) the heterogeneity and plasticity of the 
numerous cell subsets involved in FL cell growth, associated to their limited survival 
and proliferation in vitro. Nevertheless, several recent studies have provided 
interesting clues illustrating the two faces of FL microenvironment; i.e. its capacity to 
exert anti-tumor activity by itself or by potentiating the efficacy of FL-targeting drugs 
versus its capacity to favor directly and indirectly FL B-cell growth. This review will try 
to integrate them in a comprehensive view of the intricate FL cell niche. A related 
interesting question is how malignant B cells co-opt and divert their 
microenvironment to create a conducive niche in LN and BM and how this niche is 
modified after treatment and support FL relapse. A better understanding of the 
ambivalent role of FL microenvironment would be useful to select the more relevant 
biomarkers for patient stratification and prognosis. It will also make it possible to 
design new microenvironment-targeted treatments, a field that recently gained 
increasing attention in B-cell lymphomas.  
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2. Microenvironment can inhibit FL cell growth 
FL has long been considered as particularly immune responsive based on reports of 
spontaneous regressions, high response rates to monoclonal antibodies (mAb) 
associated with a long-lasting vaccinal effect, and good biological responses to 
vaccination using tumor-specific idiotype or immunogenic neoplastic cells [19-22]. 
Several immune cell subsets could contribute to this anti-tumor activity and provide 
useful biomarkers and potential therapeutic targets.  
 
2.1 Cytotoxic lymphoid cells  
CD8pos T cells are major actors of anti-tumor immunity and an increased CD8pos T-
cell infiltrate is correlated to a better FL prognosis [23]. Similarly, high levels of blood 
CD3pos, CD4pos, and CD8pos predict favorable outcome in patients treated with 
rituximab [24]. Using 3-D tissue imaging, Laurent et al. described a rich infiltrate of 
functional CD8pos cells containing granzyme Bpos lytic granules in the interfollicular 
spaces [25]. T cells at the follicular border form lytic synapse-like structures with FL B 
cells, suggesting a tonic control of malignant cell trafficking and FL progression. 
However, a global CD8pos T-cell exhaustion as well as dysfunctional synapses with 
FL B cells have been reported in biopsy specimens [26, 27]. In addition, intratumoral 
regulatory T cells (Treg) have been shown to inhibit in vitro degranulation and 
cytotoxic activity of infiltrating CD8pos T cells exposed to lymphoma B cells [28].  
Beside antigen-driven cytotoxicity of CD8pos T cells, innate anti-tumor cytotoxicity 
involved essentially NK cells and γδ T lymphocytes (Figure 1). Our knowledge of in 
situ NK cells in FL is limited, and the low frequency of CD56pos cells on malignant 
tissue sections has not been associated with the progression of the disease [29]. 
However, we could hypothesize an induction of NK-DC crosstalk by therapeutic mAb, 
which could trigger tumor antigen-specific T cell immunity [30]. Considering γδ T 
cells, Vγ9δ2 T cells recognize tumor phosphoantigens, like isopentenyl 
pyrophosphate (IPP), and are able to kill in vitro a wide variety of tumor cell lines, as 
well as primary FL B cells [31]. Whereas γδ T cells could migrate into GC within 
normal secondary lymphoid organs [32], immunohistochemistry studies revealed that 
these cells display mainly perifollicular localization and are represented at lower 
density in FL LN tissues, compared to reactive LN [33]. Moreover, those FL B cells 
retaining HVEM expression could inhibit proliferation of BTLApos infiltrating Vγ9δ2 T 
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cells [34]. In agreement, we found a lower in vitro expansion capacity of FL infiltrating 
Vγ9δ2 T cells in response to a combination of their pharmacological agonist 
bromohydrin pyrophosphate (BrHPP) with IL-2 (our unpublished data). FL B cells 
were shown to express ULBP proteins, the ligands for NKG2D activating receptor 
and an increase in circulating ULBP-responsive Vδ1 T lymphocytes have been 
described in FL patients [35]. However, the role of Vδ2neg γδ T cells in FL 
pathogenesis remains poorly understood. 
Finally, NK cells, γδ T lymphocytes, and a subset of CD8pos T cells share the capacity 
to mediate antibody-dependent cellular cytotoxicity (ADCC), an important mechanism 
of anti-tumor immune response. The association between Rituximab clinical 
efficiency and a specific polymorphism in CD16/FcγRIIIa resulting in a modulation of 
affinity for IgG1 revealed the critical role of CD16-expressing cells in the activity of 
this anti-CD20 mAb [36]. 
Overall, cytotoxic cells of both innate and adaptative immunity could efficiently kill 
lymphoma B cells but this antitumor immune response is actively counteracted by 
tumor escape mechanisms affecting immune cell recruitment and activation. 
 
2.3 Myeloid cells  
Tumor-associated macrophages (TAM) exhibit a dual role in FL pathogenesis, as 
underlined by the opposite predictive value of a high TAM content, depending on 
treatment schedule. In fact, high numbers of CD68pos or CD163pos TAM are 
associated with adverse outcome in FL patients treated with conventional 
chemotherapy, whereas this prognosis value is abrogated or even inversed when 
Rituximab is combined with chemotherapy [37-39]. These data suggest that FL TAM 
could favor tumor progression but also contribute to the clinical efficacy of antibody-
based anti-lymphoma drugs (Figure 2). Accordingly, B cell depletion with anti-CD20 
mAb in mouse models prominently depends on macrophages, and more specifically 
on their expression of activating FcγR [40]. In addition, for rituximab-mediated tumor 
clearance in human, antibody-dependent cellular phagocytosis (ADCP) mediated by 
macrophages probably plays a key role beside that of NK-mediated ADCC [41]. In 
particular, Rituximab and Ofatumumab show high direct ADCP capacities in vitro and 
elicit TNF-α release by macrophages, which could indirectly contribute to NK cell 
activation [42]. Interestingly, alternatively activated M2 macrophages were shown to 
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display in vitro a greater phagocytic capacity towards Rituximab-opsonized B cells 
from chronic lymphocytic leukemia (CLL), when compared to M1 proinflammatory 
macrophages [43]. This was associated with a differential regulation of FcγR 
expression by polarizing cytokines. In agreement, several reports demonstrate that 
IL-4 decreases expression of CD64/FcγRIa whereas IL-10 up-regulates all classes of 
FcγR and favors CD32a/FcγRIIa-mediated phagocytosis [44]. FL TAM display a 
CD16negCD32ahiCD64hi phenotype and CD32a is primarily involved in the 
phagocytosis of anti-CD20-opsonized primary FL B cells in vitro (our unpublished 
data). Altogether, the overexpression of both IL-4 and IL-10 within FL 
microenvironment [45] could modulate the TAM phenotype, including expression 
levels of FcγRs and phagocytic properties in the presence of therapeutic antibodies.  
The clinical relevance of ADCP has been further underlined by the demonstration 
that FL and DLBCL B cells overexpress CD47, a transmembrane protein that 
enables evasion of phagocytosis through binding to the inhibitory receptor signal 
regulatory protein (SIRP)-α on macrophages [46]. Accordingly, a blocking mAb 
targeting CD47 restores phagocytic activity of macrophages in vitro and synergizes 
with Rituximab for the elimination of human lymphoma in xenotransplant models in 
NOD-scid Il2rgnull (NSG) mice. It was recently demonstrated that the genetic 
determinant favoring human cell engraftment in NOD-based immunodeficient mouse 
models is a Sirpa gene polymorphism allowing recognition of human CD47 by mouse 
phagocytes and inhibiting human grafted cell engulfment [47]. This observation could 
have potential impact for the development of new xenograft models of FL. 
Altogether, TAM appear as a highly plastic cell subset involved in antitumor 
immunity, in particular through FcγR-related ADCP, a process actively inhibited by 
CD47-expressing malignant B cells. 
 
2.4 Relevance for the design of new therapies  
The demonstration that several immune cell subsets could efficiently trigger FL B-cell 
death is difficult to reconcile with the general lack of clinical response following 
classical antigen-specific immunotherapy strategies. In particular, despite promising 
proof-of-principle studies, the results of phase III randomized trials examining the 
clinical impact of idiotypic vaccination in FL were disappointing [21]. Since idiotypes 
have been shown to be immunogenic, these negative results are likely due to 
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mechanisms of avoiding immune cell recruitment, recognition, and lysis by malignant 
B cells. A better understanding of the relationships between B cells and their immune 
microenvironment will be highly useful to design new treatments that could overcome 
immune escape and enhance clinical efficacy of chemotherapy and antibody-
mediated immunotherapy (Figure 3).  
Such approaches are currently explored with immunomodulators like lenalidomide 
that is evaluated in clinical trials in FL, in combination with Rituximab. Lenalidomide 
has pleiotropic activities including a substantial capacity to activate NK cells, to 
increase T-cell proliferation and function, and to enhance macrophage-mediated 
ADCP of Rituximab-coated tumor cells [48]. The main molecular target of 
lenalidomide is the E3 ubiquitin ligase cereblon that was recently shown to trigger the 
induction of cytokine production by T cells [49]. Interestingly, FL infiltrating CD4pos 
and CD8pos T cells display immunological synapse dysfunction with impaired F-actin 
polymerization [27]. This defect could be reversed after in vitro treatment of both FL 
and autologous T cells with lenalidomide. A recent report pinpoints lenalidomide 
capacity to rescue LFA-1-dependent T-cell adhesion and motility in CLL patients by 
restoring Rho GTPase activity [50]. The relevance of this mechanism for the clinical 
activity of lenalidomide in FL remains to be evaluated.  
Another important research field is the engineering of modified antibodies with 
optimized effector properties [51]. GA101 afucosylated anti-CD20 mAb is currently 
under clinical evaluation in FL and is supposed to mediate greater NK-cell ADCC 
through a higher affinity for CD16/FcRγIIIA that abrogates the negative impact of the 
unfavorable FcRγIIIA polymorphism [42]. However, GA101 recently demonstrated 
inferior ADCP compared with rituximab suggesting that new Fc modifications are 
required to improve specific binding to CD32a and enhance phagocytosis [52]. 
Besides targeting directly tumor cells, a new generation of antibodies has been 
designed to stimulate immune cells in the microenvironment (reviewed in [53]). 
Among them, agonistic antibodies targeting the inducible co-stimulatory molecule 
CD137 could favor ADCC and T-cell activation and enhance the antilymphoma 
activity of anti-CD20 mAb [54]. Similarly, antibodies blocking KIR, the NK inhibitory 
receptor family, could be useful despite their systemic activation of resting NK cells 
[55]. Finally, promising immunological and clinical results have been obtained using 
combination of rituximab, BrHPP, and IL-2 in relapsed FL patients, suggesting that γδ 
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T cells could be activated in vivo and trigger direct cytotoxic activity as well as ADCC 
owing to their inducible CD16 expression [56]. Targeting immune cells to increase 
their effector functions should thus be considered as a promising therapeutic strategy 
in FL, in particular with the aim of optimizing mAb-driven cytotoxicity. 
 
3. Microenvironment can favor FL cell growth 
Besides its potential role in tumor eradication, FL microenvironment revealed 
individual tumor supportive activity of each cell subset, including stromal cells, TFH, or 
TAM, on malignant B-cell recruitment, survival, proliferation, and drug resistance. In 
addition, the FL cell niche should be envisioned as a dynamic network of cell 
interactions where the various cell compartments also contribute to migration, 
expansion, activation, and polarization of each other.  
 
3.1 Stromal cells  
Cancer-associated fibroblasts (CAF) are phenotypically and functionally different 
from their normal counterpart and play a key role in tumor development and 
progression in various cancer models [57]. In FL, LN and BM CAF essentially display 
some features of lymphoid stromal cells, a heterogeneous cell compartment 
organized as three specialized cell niches within normal secondary lymphoid organs 
[58, 59]: i) the mesenchymal stromal network of the T-cell zone is formed by 
fibroblastic reticular cells (FRC), which provide a foothold for antigen delivery, 
immune cell recruitment, motility, interaction, and homeostasis through the release of 
extracellular matrix components, IL-7, VEGF, nitric oxyde, and homeostatic 
chemokines CCL19, CCL21 and CXCL12; ii) follicular dendritic cells (FDC) drive 
CXCL13-dependent attraction of B cells and TFH within the GC where they promote 
the selection of high affinity B cells through the retention and presentation of antigens 
as immune complexes; iii) finally, marginal reticular cells (MRC) deliver small 
antigens to cognate B cells though specific follicular conduits. The main common 
feature of lymphoid stromal cells is to derive from resident local precursors and to 
require both tumor necrosis factor (TNF)-α and lymphotoxin (LT)-α1β2 for their 
maturation and maintenance as immunologically competent cells. In addition, human 
LN contain bona fide mesenchymal stromal cells (MSC) that can be triggered to 
adipocyte, osteoblast, and chondrocyte lineages but also to FRC differentiation in 
response to a combination of TNF-α and LT-α1β2 [60]. However, the exact origin of 
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human lymphoid stromal cells remains elusive in both normal and FL-invaded LN and 
BM. Moreover, FL LN stromal cells displayed altered in situ phenotype compared to 
normal LN, including a uniform and marked activation of transglutaminase expressing 
FRC-like network whereas follicle stromal cells progressively loose classical FDC 
markers [61-63]. The mechanisms and consequences of these phenotypic 
modifications are unknown, in particular because functional analysis of native stromal 
cells remains a highly challenging issue. 
MSC obtained after culture of invaded FL BM (FL-MSC) support more efficiently the 
growth of malignant B cells than MSC obtained from healthy donor BM (HD-MSC) 
[64]. To better understand this result, we compared the gene expression profile of 
FL-MSC and HD-MSC and revealed that FL-MSC in the BM are ectopically 
committed to a FRC-like differentiation. In agreement, FRC-like cells obtained from 
HD-MSC in response to TNF-α and LT-α1β2 priming are more powerful to drive 
malignant B-cell survival than HD-MSC themselves [60]. The tumor-promoting 
capacity of FL-MSC remains to be molecularly understood (Figure 4).  
Stromal cells have been involved in the recruitment of malignant FL B cells through 
the release of CXCL12 and CXCL13 [60, 65]. They also contribute directly and 
indirectly to B-cell survival and drug resistance. Accordingly, interaction of malignant 
B cells and FDC was recently suggested to upregulate MDR1, an ABC transporter 
triggering multidrug resistance in FL B cells compared to DLBCL [66]. Among the 
paracrine supportive factors produced by stromal cells, Hedgehog (Hh) ligands, B 
cell-activating factor of the TNF family (BAFF), IL-15, hepatocyte growth factor 
(HGF), and the adhesion molecule CD106 have all been proposed to contribute to 
the antiapoptotic effect of stromal cells on normal and malignant GC B cells [67-74]. 
Paracrine Hh signaling might also favor stroma-mediated chemotolerance in indolent 
lymphomas by upregulating the drug transporter ATP-binding cassette (ABC)G2 [75], 
whereas adhesion of VLA-4pos FL B cells to CD106pos stromal cells protects them 
from rituximab-induced apoptosis [76]. The role of FDC-derived Wnt5a, Notch 
ligands, and PGE2 in GC-derived lymphomas has not been explored to date. In 
addition, the question of whether stromal cells transfer paracrine information to 
malignant B cells remains unanswered. BM-MSC from patients with multiple 
myeloma release exosomes containing specific microRNA and proteins that support 
the growth and dissemination of malignant plasma cells [77]. It would be important to 
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clarify the role of such microvesicles in the crosstalk between stromal cells and B 
cells in FL.  
Finally, beyond the numerous individual factors suspected to trigger stromal 
protection of neoplastic cells, a recent paper revealed that BM-MSC promote 
gluthatione synthesis and survival of CLL B cells [78]. Given the central place of 
oxydative metabolism in cancer development, it is tempting to speculate that such 
mechanism could also be involved in the supportive activity of stromal cells in FL 
context.  
FL stromal cells are likely organizers of FL cell niche. In particular, FL-MSC 
overexpressed CCL2 that favors the recruitment of monocytes and triggers their 
differentiation into proangiogenic and anti-inflammatory TAM-like macrophages [64]. 
Interestingly, MSC isolated from spontaneous lymphomas in mouse also overexpress 
CCR2 ligands and recruit more macrophages than BM-MSC [79]. In addition, IFN-γ 
primes human and mice FRC to produce the immunosuppressive enzymes 
indoleamine-2,3 dioxygenase (IDO) and nitric oxide synthase 2 (iNOS), respectively 
[80, 81]. Since IFN-γ is upregulated within FL microenvironment [80], such primed 
FRC could thereafter inhibit T-cell proliferation and contribute to tumor immune 
escape.  
In conclusion, stromal cells play a central role in FL pathogenesis through both a 
direct tumor B-cell supportive activity and an indirect effect on the orchestration of FL 
cell niche. 
 
3.2 CD4pos T cells  
Genes related to CD4pos T cells represent a prominent part of the FL specific 
prognostic signature at diagnosis emphasizing the pivotal role of this subset (Figure 
1). Despite a global profile of exhausted T cells associated with a high proportion of 
PD1 and/or TIM3pos cells [26, 82], FL helper T cells also display a more activated 
phenotype than reactive LN helper T cells suggesting a more complex phenotype 
than previously anticipated [83]. In agreement, fully functional PD-1-expressing TFH 
are enriched within FL LN thus challenging the idea of a classical anergic T-cell-rich 
tumor niche [45]. TFH were initially identified as CD4pos T cells expressing CXCR5, 
allowing their localization in follicular areas of secondary lymphoid organs. Recent 
data broadened the definition of this compartment, and defined it as a distinct helper 
T-cell lineage, under the control of BCL6, and playing a central role in GC B-cell 
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localization, selection, and differentiation in normal follicles [84]. Nevertheless, beside 
this unique functional definition, the TFH compartment is more heterogeneous than 
previously assumed, and could be subdivided into several subsets, based on the 
secretion of various cytokines formerly assigned to other helper T cell lineages, i.e. 
IFN-γ, IL-4, or IL-17 shared with Th1, Th2, and Th17 cells; respectively. FL-TFH 
display a specific gene expression profile compared to tonsil-TFH, with an 
overexpression of IL4, IL2, IFNG, and TNF [85]. High levels of IL-4, essentially 
produced by TFH, have been associated with a STAT6 and Erk-dependent FL B-cell 
activation [45, 86] and recent evidences highlighted a potential role of TFH-derived 
CD40L in malignant B-cell survival [85, 87]. Beside this direct protumoral activity, FL-
TFH could also modulate the FL supportive niche through their expression of TNF and 
LTA that sustain differentiation and maintenance of the B-cell supportive lymphoid 
stroma network [60]. In addition, FL-TFH secrete high amounts of IFN-γ, thus inducing 
the expression by stromal cells of the tryptophan-catabolizing enzyme IDO [80] and 
could contribute by their overexpression of IL-4 to the polarization of TAM within the 
malignant cell niche [88]. 
Analyzes of dissociated FL biopsies revealed also a higher frequency of Treg 
compared with non-malignant LN or tonsils [85, 89]. Treg have been experimentally 
described to inhibit the anti-tumor immune responses in FL by suppressing the 
proliferation and activity of intratumoral CD4pos and CD8pos T cells [28, 89]. Elevated 
levels of soluble IL-2Rα have been involved in the inhibitory activity of FL-Treg and 
predict reduced survival in FL [90]. More importantly, an excessive number of 
Foxp3posCXCR5hi follicular Treg (TFR) has been specifically reported in FL neoplastic 
follicles. Strikingly, the follicular localization of Foxp3pos T cells rather than their 
absolute number was recently associated with a worse overall survival, suggesting 
that TFR are the more relevant Treg subset for FL biology [91]. These cells share 
phenotypic characteristics with TFH, and express a higher level of BCL6, the master 
regulator of TFH differentiation pathway, than classical Treg [85]. TFR also strongly 
express the co-stimulatory molecule ICOS, as reported for a subset of Treg with 
strong suppressive functions and able to induce IL-4-secreting T cells [92]. 
Suppressive TFR have also been described in mice. They control the GC reaction by 
limiting TFH number and inhibiting the selection of non-cognate B cells [93]. 
Nevertheless, the targets of the specific FL-TFR subset are currently unknown. It is 
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tempting to speculate that FL-TFR inhibit anti-tumor responses, thus explaining the 
worse prognosis associated with their expansion. However, we could not exclude 
that FL-TFR also contribute to a limitation of the FL-TFH compartment, in agreement 
with a lower proportion of KI67pos FL-TFH, compared to tonsil-TFH (our unpublished 
data). If this hypothesis is confirmed, the high proportion of FL-TFH should result from 
a preferential commitment of activated CD4pos T cells into TFH differentiation pathway, 
or an increased survival of differentiated TFH in response to tumor-specific 
surrounding growth factors, rather than a proliferation of a mature TFH compartment.  
Altogether, these results highlight the role of various CD4pos T-cell subsets in FL B-
cell growth as well as immune escape. In particular, TFH and Treg are strongly 
modulated both quantitatively and qualitatively during FL pathogenesis. 
 
3.3 Myeloid cells  
Although several studies have proposed TAM number as a prognostic marker, 
knowledge of their direct role in B-cell growth and how they cooperate with 
neighboring infiltrating T cells and stromal cells is still rudimentary (Figure 2). BAFF is 
a well-known myeloid-derived B-cell growth factor. Even if BAFF expression is not 
increased in FL patients [94], a polymorphism in TNFSF13B/BAFF was associated 
with an increased risk of developing FL, whereas a germline mutation in 
TNFRSF13C/BAFF-R was specifically detected in 10% of FL patients in association 
with a stronger BAFF-induced signaling [95, 96]. Another potential TAM-mediated 
pathway in FL is BCR signaling. In fact, whereas a recent study suggests that BCR 
from a subset of FL patients recognize self-antigens potentially retained on the 
surface of FDC [97], the majority of FL B cells express mannosylated BCR able to 
interact with C-type lectins DC-SIGN (CD209) and Mannose Receptor (CD206) 
independently of antigens [15, 16]. CD209 and CD206 are known to be upregulated 
on M2 macrophages and on TAM in solid tumors [98], a situation mirrored in FL by 
the overexpression of IL-4 by TFH [45]. FL-TFH also overexpress CD40L that both 
increases IL-15Rα expression on myeloid cells [99] and confers IL-15 sensitivity to B 
cells through induction of STAT5 expression and activation [70]. In agreement, FL-
TAM overexpress IL15 compared to tonsil macrophages and FL B cells overexpress 
STAT5A compared to normal GC B cells. Interestingly, IFN-γ, which is also 
upregulated in FL microenvironment [80], was shown to increase the migration of 
macrophages in response to CCL2 through an upregulation of STAT1 expression 
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[100]. Such activation loop should be important for the recruitment of macrophages 
by CCL2hi FL stromal cells and the presence of STAT1posCD68pos macrophages in 
the vicinity of FL B cells was associated with unfavorable outcome [101]. Finally FL-
TAM could contribute to local immune escape through the release of 
immunosuppressive molecules like IL4I1 [102] but also to angiogenesis. Accordingly, 
increased angiogenic sprouting correlates both with elevated numbers of CD163pos 
macrophages and poor prognosis [103]. In parallel to the description of in situ TAM, 
circulating CD14pos HLA-DRlo suppressive monocytes have been identified in B-cell 
NHL [104] and the absolute monocyte count is inversely correlated with overall 
survival in FL and DLBCL [105]. Overall, myeloid compartment display specific 
features in FL and contribute to FL pathogenesis through the release of tumor growth 
factors, proangiogenic molecules, and immunosuppressive mediators. 
3.4 Relevance for the design of new therapies  
Since interaction of FL B cells with their microenvironment is postulated to be an 
important mediator of drug resistance and disease relapse, targeting B-cell adhesion 
and/or retention within tumor niches has recently emerged as a promising therapeutic 
approach (Figure 3). Anti-VLA-4 mAb natalizumab has been shown to overcome 
stroma-mediated resistance to Rituximab [76]. In addition, disrupting the 
CXCL12/CXCR4 axis using the CXCR4 antagonist perixafor (AMD3100) or cell-
penetrating peptides targeting CXCR4 may augment the effects of anti-CD20 mAb 
[106, 107]. Interestingly, the Btk inhibitor PCI-32765, the PI3K inhibitor GS-1101, and 
Syk inhibitors do not only target BCR signaling but also impair chemokine networks 
and reduce CLL cell retention in protective microenvironment [108-110]. The 
combination of these two properties could be highly useful in FL. Lenalidomide also 
decreases CXCL12 production by stromal cells and alters CLL migration by targeting 
Rho protein activity [111, 112]. Finally, the tyrosine kinase inhibitor imatinib was 
demonstrated to impair xenografted lymphoma B-cell growth through a direct 
targeting of vascular mural cells resulting in loss of tumor vascular integrity [113]. 
This innovative finding paves the way for the introduction of antiangiogenic agents in 
our therapeutic arsenal in FL. 
Besides stromal cells, CD4pos T-cell help is crucial for FL survival and growth and 
represents an interesting druggable target. Antagonist mAb to PD-1 and PD-L1 
showed both a good safety profile and antitumor activity in some metastatic cancers 
[114]. They are supposed to block inhibitory PD-1 signaling on tumor infiltrating T 
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cells or to deplete PD-1pos anergic T cells depending on antibody isotype. In FL, PD-1 
is not only expressed on anergic T cells but also on fully functional TFH and TFR, and 
PD-L1/PD-1 pathway has been recently demonstrated to inhibit proliferation and 
function of both cell types [115, 116]. The use of anti-PD-1 mAb in this specific 
context should thus be highly valuable but would also benefit from extensive patient 
monitoring to unravel the exact target of these drugs. Of course, the recent 
development of other immune-checkpoint inhibitors, such as anti-CTLA4 mAb should 
also be considered for patients with FL.  
Beyond stimulation of effector immune cells, inhibition of protumoral T and stromal 
cells through kinase inhibitors or antagonistic mAb emerges as a valuable 
therapeutic approach in FL. 
 
3. Malignant B cells can subvert their microenvironment  
It is now well-established that tumor cells could subvert their molecular and cellular 
environment to favor their own growth, and to minimize anti-tumor immune response. 
Accordingly, the recruitment and polarization of the various microenvironment cell 
subsets in FL is at least partly governed by the malignant clone (Figures 1 & 4).  
Indeed, FL B cells directly contribute to the differentiation and maintenance of the 
dense FRC meshwork within invaded LN [60]. This FRC commitment is partly 
dependent on TNF-α secretion by malignant B cells, as exemplified for the induction 
of CCL2 in HD-MSC after contact with primary FL B cells. Invasion of BM by 
malignant GC B cells expressing TNF-α and LT-α1β2 likely induces ectopic 
lymphoid-like stromal cells. 
Malignant B cells also modify their chemokine environment through a direct secretion 
of CCL22 that recruits Treg. In addition, they contribute to the polarization of helper T 
cells. In particular, GC-derived lymphomas skew the balance of Th17 versus Treg 
differentiation in favor of an increased frequency of induced Treg, and both CD27-
CD70 and CD28-CD80/CD86 axes are involved in this process [117, 118]. Moreover, 
induction of TIM-3 on anergic T cells relies on malignant B-cell-derived IL-12 [26] 
whereas expression of multiple inhibitory ligands on B cells has been proposed to 
trigger T-cell synapse defect [119]. Despite data suggesting a thymic origin of mice 
TFR in physiological conditions [93], we could not exclude that the specific FL-TFR 
subset emerges at least in part from a tumor-driven in situ conversion of TFH into 
induced Treg. In support of this hypothesis, a strong correlation exists between FL-
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TFH and FL-TFR contents [85]. Whereas the mechanisms of FL-TFH expansion remain 
unknown, they should arise from a preferential GC-recruitment and/or commitment of 
activated helper T cells into TFH. FL B cells could be involved in this process through 
their overexpression of IL-6 and ICOS ligand (ICOS-L), compared to tonsil GC B cells 
(our unpublished data). First, it is now well documented that IL-6, in association with 
IL-21, promotes BCL6 expression in activated CD4pos T cells [120]. Second, ICOS-L 
expression by follicular bystander B cells has been recently demonstrated to control 
the recruitment of activated CD4pos T cells into GC allowing their further 
differentiation into TFH independently of cognate T-B or T-DC interaction [121]. In the 
context of FL, such co-stimulation independent function of ICOS is presumably 
important, as suggested by the fully polyclonal repertoire of infiltrating FL-TFH (our 
unpublished data). Thus, FL B cells are able to trigger recruitment, polarization, and 
maintenance of CD4pos T cells that in turn promote their survival and growth. 
 
4. Concluding remarks 
Genetic and functional studies corroborate the general concept that immune and 
stromal microenvironment plays a proactive role in the development and progression 
of FL and determines clinical behavior and response to treatment. The major goal of 
numerous recent studies was to unravel the different facets of FL cell niche and to 
define how they interact with each other. However several burning questions remain 
unsolved. Longitudinal follow-up of microenvironment composition will be helpful to 
define the kinetic of B cell/microenvironment bidirectional interactions. When do the 
first modifications of LN and BM niches occur and more specifically could some of 
them be detected at the FLLC pre-malignant stage? Comparison of 
microenvironment composition at diagnosis, in the context of residual disease, and in 
relapse would be instrumental to identify the minimal cell niche protecting malignant 
B cells from drug-induced cytotoxicity and to better understand the impact of 
treatments on the various microenvironment cell subsets. The role of the 
microenvironment in the selection of malignant B-cell subclones should be further 
analyzed. In particular, what are the molecular features of BM versus LN FL cells 
depending on their specific cell niche? Altogether, developing new tools to better 
understand microenvironment network may provide innovative tailored strategies to 
disrupt supportive niches whereas taking advantage of anti-lymphoma infiltrating 
cells.  
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Figure Legends 
 
Figure 1. Dual role of infiltrating T/NK cells in follicular lymphoma cell niche 
FL-TFH support malignant B-cell growth through CD40L and IL-4 signaling. 
Conversely, cytotoxic CD8pos T cells, γδ T cells, and NK cells display anti-tumoral 
activity and CD16-mediated ADCC is a major mechanism of action of Rituximab 
mAb. FL B cells subvert antitumor response leading to T-cell immune synapse 
dysfunction and T-cell exhaustion, to a preferential recruitment of Treg, and to an 
imbalance in Treg/Th17 polarization in favor of induced Treg. In addition, malignant 
cells could encourage TFH commitment through their overexpression of ICOS-L and 
IL-6. 
 
Figure 2. Dual role of infiltrating macrophages in follicular lymphoma cell niche 
Tumor-associated macrophages (TAM) contribute directly to malignant B-cell growth 
through BCR, IL-15, and BAFF signaling, and display proangiogenic and 
immunosuppressive properties. Conversely, FL-TAM participate to the therapeutic 
efficacy of anti-CD20 mAb through B-cell phagocytosis, a process inhibited by 
CD47/SIRPα axis, and activation of cognate cytotoxic T cells. FL-TFH cooperate with 
FL-TAM for promoting STAT5 activation in B cells and produce cytokines, including 
IL-4, IL-10, and IFN-γ, involved in TAM migration, polarization, and function. 
 
Figure 3. New drugs to target FL tumor microenvironment 
Lenalidomide exerts pleiotropic activities including activation of NK cells, T cells, and 
macrophage-mediated antibody dependent phagocytosis. Similarly, inhibitors of Btk 
and Syk exhibit broader mechanisms of action than initially anticipated and target not 
only BCR-mediated signal but also B cell/stromal cell interactions. Stromal cell niche 
could also be disrupted using CXCR4 antagonists and anti-VLA4 mAb. Several 
therapeutic mAb, including anti-PD-1, anti-CTLA4, anti-CD47, and anti-CD137, target 
tumor immune cells instead of malignant B cells whereas BrHPP is a specific γδT-cell 
agonist. Finally, imatinib was recently shown to compromise tumor-associated 
microvasculature through a selective inhibitory effect on pericytes. 
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Figure 4. Role of infiltrating stromal cells in follicular lymphoma cell niche 
Stromal cells recruit and support directly the growth of FL B cells through a 
combination of chemokines, adhesion molecules, and cytokines. The role of antigen-
presentation by FDC remains speculative. This protumoral property is strongly 
influenced by the local cytokine context. TNF-α (TNF) and LT-α1β2 (LT) produced by 
malignant B cells and TFH trigger stromal cell engagement into lymphoid stroma 
differentiation whereas IFN-γ could favor production of T-cell inhibitory enzyme IDO. 
Finally, FL stromal cells efficiently recruit TAM through the specific release of CCL2 
chemokine. 
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